Olverembatinib (HQP1351): a third-generation tyrosine kinase inhibitor in the treatment of hematologic and solid malignancies—a comprehensive review of clinical outcomes
Key Points
Olverembatinib demonstrates promising clinical outcomes in treating hematologic and solid malignancies.
Key evidence includes improved response rates reported across various studies, showing an efficacy rate of up to 80%.
The assessment follows a comprehensive review of clinical outcomes based on multi-center trials and case reports.
Further validation in larger patient populations is necessary to confirm these findings and optimize treatment protocols.
Olverembatinib (HQP1351): a third-generation tyrosine kinase inhibitor in the treatment of hematologic and solid malignancies—a comprehensive review of clinical outcomes | Synapse